Abstract
<h3>Background</h3> While immunotherapy is profoundly efficacious in certain cancers, its success is limited in cancers with lower mutational burdens, such as gliomas.<sup>1</sup> Therefore, investigating neoantigens beyond those from somatic mutations...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
